Bioteknologia

Biotechnology in France

LUUKKAINEN Annamari - 24-avr.-2014 16:07:26

Biotechnology in France Even though biotechnologies may be a recent sector of business activity, France has succeeded in developing real know-how that is gaining international recognition.   When it comes to biotechnologies, the French are cutting edge. According to Leeme, the federation of French medical companies, today France numbers 388 biotechs in the health field in France. Biotech France, another French association for biotech companies, indicates that a third of these companies have been in existence for over 10 years. Yet the number of creations in this field is exponential. To get an idea, 50 companies were started in 2012. Unheard of! Proof that there is a real entrepreneurial effervescence when it comes to this research in France. Young start-ups for the most part, French biotechs are mainly Small Medium sized companies. Only 4% of them have over 100 employees. On average, they employ 22 people. As to the type of activity, most of the French companies specialized in human sciences with therapeutic products are concentrated on cancer treatments. “The French have developed a full-fledged know-how on cardio-vascular devices, infectious diseases, dermatology, blood diseases and for surgery,” explains Yves Germani, Ubifrance’s manager for the health sector in North America.   French enterprises don’t just do research; they discover! Altogether, the French biotech industry generated 261 Million Euros in turnover in 2011, compared with 186 Million in 2010. As for companies on the stock market, they generate 369 Million Euros in turnover. Concerning the pipeline, the expression used to indicate the number of molecules being developed, France is 4rth, behind the United Kingdom, Germany, Switzerland and Israel. Quite a solid ranking, but which should nevertheless be improved. When their results are examined in detail, we see that depending on the stage of development, French companies create more products in the pre-clinic phase, in other words, all those that have been carried out before the clinical trial with patients, which is completely logical. Between the start of development on a new medicine, a molecule and its release on the market can sometimes take up to 10 years. Unfortunately, the consequence of this is that a number of products fall by the wayside. To be noted, however, is one undeniable fact: since 2008, French companies have sold more and more products. To put it another way, as Yves Germani points out, French companies don’t just do research; they discover!”   An increase of 63% in investment   www.ubifrance.com/french-exporters-directory/companies.aspx


Join the 4th edition of BioFit on December 1st & 2nd 2015 in Strasbourg, France +1 day SPECIAL INVITATION to a Franco-German-Swiss Excellence Event on November 30th

Business France, head office - 04-nov.-2015 10:25:37

  BIOFIT is the leading business convention in Europe for open Innovation, technology transfer and collaborative research in Life Sciences. More than 1300 participants will attend the 2015 edition, which will be held in Strasbourg (Alsace region), at the heart of the Franco-German-Swiss BioValley Cluster, a center of excellence for therapeutic innovation I www.biofit-event.com   Public & Private collaborations   BioFIT is the leading partnering event in Europe for Open Innovation, technology transfer and collaborative research in the field of Life Sciences, with the highest attending rate of academia, TTOs and research institutes together with big pharma, emerging and small biotech companies, medtech and diagnostics companies.   Engage new partnerships Foster the emergence of collaborative projects Intensify the flow of licenses in the field of life sciences   Who will you meet?   The event gathers leaders from pharma, biotech, medtech, IVD companies, investors, as well as professionals from technology transfer and academia.   Website : http://www.biofit-event.com /   Registration for Biofit : http://www.biofit-event.com/registration/registration-fees/  


BIOTEKNOLOGIAN ALAN RANSKALAISVIERAILU POHJOISMAIHIN - 3. 7. 10.2011

Vincent JOLY - 12-déc.-2011 11:21:02

Terveysalan bioteknologian tärkeä asema ja hyvä maine Pohjoismaissa ovat houkutelleet kilpailukykykeskusten, yritysten, laboratorioiden ja sairaaloiden edustajista koostuvan ranskalaisvaltuuskunnan vierailulle Tanskaan, Ruotsiin ja Suomeen 3.-7. lokakuuta. Delegaatio vieraili Kööpenhaminassa, Lundissa, Tukholmassa ja Turussa tarkoituksenaan käydä eri kohteissa, joissa delegaation jäsenillä on omia tapaamisia. Delagaation tarkoituksena oli tutustua meneillään olevaan tutkimukseen bioteknologian eri aloilla, kuten neurotieteissä, onkologiassa, tulehdussairauksissa, immunologiassa jne. luodakseen tutkimukseen liittyviä ja kaupallisia kumppanuussuhteita. Innovaatio on Ranskalle talous- ja teollisuuspolitiikan ytimessä. Kilpailukykykeskukset vastaavat paremmasta koordinaatiosta tutkimuksen ja kehityksen alalla sekä teknologian siirtymisessä korkeakouluilta yrityksille kokoamalla saman tahon yhteyteen niin yksityisen ja akateemisen tutkimuksen, yritysmaailman kuin opetusalankin toimijat. Tällä tavoin voidaan tukeutua syntyvään synergiaan ja innovatiivisiin yhteistyöhankkeisiin, joiden avulla yritykset voivat saada jalansijaa kansainvälisillä markkinoilla samalla kun innovaatio hyödyttää teollisuutta ja potilaita. Alla seitsemän vuonna 2005 valtion aloitteesta luodun bioteknologiaan erikoistuneen klusterin tiedot. Alsace Biovalley : http://www.alsace-biovalley.com/fr/Alsace-BioValley-web-site-123.html Atlanpole Biothérapie : www.atlanpolebiotherapies.eu Cancer Bio Santé : www.cancerbiosante.fr . Eurobiomed : http://www.eurobiomed.org/en/eurobiomed/ Lyonbiopole :   http://www.lyonbiopole.org/index-en.html Medicen Paris Region : http://www.medicen.org/en Nutrition Santé Longévité :   http://www.pole-nsl.org/poleNSL_eng.html Vierailua tukee talous- ja teollisuusministeriön alainen kilpailukykyhallinto DGCIS ja Ubifrance (yritysten kansainvälistymistä edistävä FinProta vastaava organisaatio). Lisätietoja: Nicolas REDON, nicolas.redon@ubifrance.fr - +358 9 759 945 14


Meistä
  Tiina Sounela Senior Business Development Manager   T: + 3589 7599 4514 - GSM: + 358 50 379 9622 tiina.sounela@businessfrance.fr    Business France Yrjönkatu 36, 00 100 Helsinki Finland www.businessfrance.fr     AND   Sophie Richard Trade Development Advisor T: + 3589 7599 4519 sophie.richard@businessfrance.fr   Business France Yrjönkatu 36, 00 100 Helsinki Finland www.businessfrance.fr                                     

Lue lisää

Facebook
Lehdistö & Mediagalleria